Helical Fusion Achieves Milestone Toward Commercial Fusion Energy, Advancing to Integrated Demonstration Device
27.10.2025 04:00:00 CET | Business Wire | Press Release
Helical Fusion Co., Ltd., a world-leading developer of the Helical Stellarator, has completed a critical performance test of a high-temperature superconducting (HTS) coil—a core component of commercial fusion reactors. The company has now commenced manufacturing and construction of its integrated demonstration device, Helix HARUKA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026597002/en/
Helical Fusion members celebrating the successful HTS test with an “HTS Graduation!” sign and graduation caps
Watch the key points of this release in a 2-minute video: https://youtu.be/UhgQHfKtvow
Helical Fusion is the only company in the world building upon expertise in the Helical Stellarator approach, accumulated for more than 60 years at national institutes and national universities, which has been proven to possess the optimal characteristics for commercial power generation. As the sole inheritor of this knowledge from the National Institute for Fusion Science (NIFS), Helical Fusion is driving the Helix Program to realize the world’s first commercially viable fusion power plant using the Helical Stellarator.
Under the Helix Program, the company aims to complete performance tests of its two key technologies—HTS magnets and the integrated blanket/divertor system—by the end of the 2020s. By the 2030s, Helical Fusion plans to achieve full system integration through Helix HARUKA and begin steady-state power generation with its fusion pilot plant, Helix KANATA.
About the Performance Test
Significance
This milestone marks the world's first successful demonstration of an HTS coil constructed with a fully-functional large-scale conductor:
- The coil is based on a conductor cable designed for commercial fusion power plants' scale use 1
- The test replicated the magnetic environment inside a fusion device 2, including both self-generated and external magnetic fields
- Successfully conducted a current test under superconducting conditions
Using NIFS’s unique large-diameter, high-field testing facility, the conductor achieved stable superconducting current flow at 40 kA under a 7-tesla external magnetic field at 15 K (-258°C).
This result establishes Helical Fusion as one of the world’s leading contenders in the race toward commercial fusion energy and meets the technical threshold required to advance to the integrated demonstration device, Helix HARUKA.
Strong Collaboration with the National Laboratory and the Government
Since its founding in 2021, Helical Fusion has worked closely with NIFS through multiple joint research initiatives. In March 2024, a dedicated joint research team and lab space were established at NIFS to accelerate the development of HTS magnets and blanket/divertor systems - a model of Japan’s public-private partnership in fusion innovation.
The company’s progress is supported by Japan’s SBIR Phase 3 program, the first national grant scheme dedicated to fusion energy under the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The establishment of this program was strongly initiated by Ms. Sanae Takaichi, the current Prime Minister of Japan, during her tenure as Minister for the Cabinet Office, where she championed the inclusion of fusion energy as a national strategic priority. Helical Fusion received the program’s largest amount, JPY 2 billion (≒USD 13 million).
Importance of HTS Magnet Development
Fusion reactors require magnetic fields strong enough to confine plasma exceeding 100 million degrees Celsius. For commercial plants, these fields must be generated efficiently and compactly — a challenge that makes HTS technology indispensable.
While many companies produce HTS materials, only a few possess the capability to design and engineer full-scale superconducting systems for real reactor environments. Helical Fusion’s success demonstrates its technical leadership in this domain.
About the Helix Program
The Helix Program targets the launch of the world’s first commercially viable fusion power plant in the 2030s through its Fusion Pilot Plant, Helix KANATA. The program defines three essential requirements for commercially viable fusion power:
- Steady-state operation: 24/7/365 stable performance
- Net electricity output: generating more energy than it consumes
- Maintainability: regular, efficient component maintenance
Out of more than 50 fusion development projects worldwide—spanning tokamak and laser-based approaches—the Helical Stellarator is uniquely capable of meeting all three criteria with existing technologies. The Helix Program aims to be the world’s first initiative to realize all of these requirements by the 2030s.
Powered by a strong partnership with NIFS and supported by Japan's world-class manufacturing industry, Helical Fusion is committed to leading the global fusion energy sector—a market expected to reach trillions of dollars in scale in the coming decades.
Comment from Co-Founder, CEO Takaya Taguchi
This achievement is undoubtedly a remarkable laboratory milestone born from Japan’s strong collaboration between industry, government, and academia.
Yet, more importantly, it marks a global turning point — a moment when everyone pursuing or believing in commercial fusion must recognize Helical Fusion as one of the most promising contenders for realization.
I am immensely proud of our joint team with the National Institute for Fusion Science (NIFS) — the giant of fusion research from which our company originated — and deeply grateful to our Japanese manufacturing partners whose craftsmanship made this success possible.
As we move forward to the next stage, we invite the world to watch closely and share in the excitement of what comes next.
Comment from Co-Founder, CTO Junichi Miyazawa
The development of high-temperature superconducting (HTS) magnets marks a powerful shift from laboratory research to real-world implementation.
Over years of dedicated work, the global fusion community has advanced material and magnet technologies that did not even exist when I began our research — technologies that now give us strong confidence in achieving commercial fusion power.
This successful test is the culmination of many years of development and close collaboration with partners across academia and industry. We will channel our deepest gratitude into the continued progress of Helix HARUKA and Helix KANATA.
About Helical Fusion Co., Ltd.
Helical Fusion is a Japan-based startup developing the world’s first commercially viable net power fusion plant, leveraging the expertise of the Helical Stellarator and inheriting more than 60 years of national fusion research.
Helical Fusion has raised JPY 5.2 billion (≈USD 34 million) to date and targets commercial operation in the 2030s under its “Helix Program”.
| ___________________________________ |
1 This coil is made using advanced high-temperature superconducting (HTS) technology, and it was constructed without electrical insulation. Among all HTS coil technologies, this marks the world’s first successful test of uninsulated a large-scale HTS conductor-based coil. |
| 2 “the magnetic environment inside a fusion device” refers to a setting in which external magnetic fields—separate from those generated by the coil itself—are present, creating complex electromagnetic interactions between multiple currents through the magnetic field. In future fusion power plants, such environments are expected to include intense radiation, neutron flux, and even stronger magnetic fields. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20251026597002/en/
Contacts
Media contact: contact@helicalfusion.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom